Desmethylsertraline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Desmethylsertraline
Accession Number
DB14071
Description

Desmethylsertraline is a metabolite of sertraline.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 292.2
Monoisotopic: 291.0581549
Chemical Formula
C16H15Cl2N
Synonyms
  • Demethylsertraline
  • N-Demethylsertraline
  • N-Desmethylsertraline
  • Norsertraline
External IDs
  • CP 62508
  • CP-53261

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UP-glycoprotein 1
inhibitor
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Desmethylsertraline.
AmifampridineThe risk or severity of seizure can be increased when Desmethylsertraline is combined with Amifampridine.
AmobarbitalThe therapeutic efficacy of Amobarbital can be decreased when used in combination with Desmethylsertraline.
BrexanoloneThe therapeutic efficacy of Brexanolone can be decreased when used in combination with Desmethylsertraline.
BrivaracetamThe therapeutic efficacy of Brivaracetam can be decreased when used in combination with Desmethylsertraline.
BupropionThe risk or severity of seizure can be increased when Bupropion is combined with Desmethylsertraline.
ButalbitalThe therapeutic efficacy of Butalbital can be decreased when used in combination with Desmethylsertraline.
CannabidiolThe therapeutic efficacy of Cannabidiol can be decreased when used in combination with Desmethylsertraline.
CarbamazepineThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Desmethylsertraline.
CenobamateThe therapeutic efficacy of Cenobamate can be decreased when used in combination with Desmethylsertraline.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
CJJ71O9BE8
CAS number
87857-41-8
InChI Key
SRPXSILJHWNFMK-ZBEGNZNMSA-N
InChI
InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16-/m0/s1
IUPAC Name
(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
SMILES
[H][[email protected]]1(N)CC[[email protected]@]([H])(C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12

References

General References
Not Available
ChemSpider
102729
BindingDB
50367182
ChEMBL
CHEMBL40733
ZINC
ZINC000006117444
Wikipedia
Desmethylsertraline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.79e-05 mg/mLALOGPS
logP4.92ALOGPS
logP4.72ChemAxon
logS-6.5ALOGPS
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity80.97 m3·mol-1ChemAxon
Polarizability30.37 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. O'Brien FE, Dinan TG, Griffin BT, Cryan JF: Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012 Jan;165(2):289-312. doi: 10.1111/j.1476-5381.2011.01557.x. [PubMed:21718296]
  2. Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, DeVane CL: Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4. [PubMed:18239278]
  3. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, Ram E, Weizman A: Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol. 2008 Aug;33(2):277-86. [PubMed:18636148]

Drug created on June 14, 2018 16:51 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates